Satellos Bioscience Inc. ( $MSLE ): Can Shares Reach the $20 Target? (Check any stock’s price target on Tickeron.) The selected price target is $20 per share, roughly double the stock's recent closing price near $9.75. The strongest bullish factor is a clinical catalyst pipeline for SAT-3247, including the TRAILHEAD study in adults and the Phase 2 BASECAMP readout expected in late 2026. Analysts are broadly constructive, with price targets clustered between $14 and $40 and a median near $20 $ANL $RVMD $ACHV $BBOT $BNTX